Eisai Loses Bid For Longer Exclusivity In FDA Delay Fight
Eisai Inc. lost its bid to require the U.S. Food and Drug Administration to extend the market exclusivity periods for two of its drugs when a Washington, D.C., federal judge found...To view the full article, register now.
Already a subscriber? Click here to view full article